Financhill
Sell
27

BIO Quote, Financials, Valuation and Earnings

Last price:
$228.05
Seasonality move :
-0.23%
Day range:
$227.76 - $230.83
52-week range:
$215.38 - $387.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.53x
P/B ratio:
0.93x
Volume:
271.5K
Avg. volume:
311.1K
1-year change:
-19.9%
Market cap:
$6.2B
Revenue:
$2.6B
EPS (TTM):
-$76.20

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BIO
Bio-Rad Laboratories
$573.2M $1.78 -3.73% -86.75% $318.67
AKYA
Akoya Biosciences
$19.3M -$0.23 -21.86% -14.82% $1.88
AZTA
Azenta
$140.8M $0.07 -13.41% 86.12% $41.60
BNGO
Bionano Genomics
$6.3M -$1.11 -11.23% -97.97% $7.33
BRKR
Bruker
$772.5M $0.44 1.31% 799.94% $55.13
HBIO
Harvard Bioscience
$19.2M -$0.04 -18.82% -64.29% $3.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BIO
Bio-Rad Laboratories
$229.15 $318.67 $6.2B -- $0.00 0% 2.53x
AKYA
Akoya Biosciences
$1.22 $1.88 $60.8M -- $0.00 0% 0.76x
AZTA
Azenta
$27.10 $41.60 $1.2B -- $0.00 0% 2.06x
BNGO
Bionano Genomics
$3.70 $7.33 $12.4M -- $0.00 0% 0.16x
BRKR
Bruker
$36.97 $55.13 $5.6B 71.10x $0.05 0.54% 1.62x
HBIO
Harvard Bioscience
$0.28 $3.00 $12.6M -- $0.00 0% 0.14x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BIO
Bio-Rad Laboratories
15.25% 1.030 17.86% 4.12x
AKYA
Akoya Biosciences
108.34% 0.070 110.41% 0.36x
AZTA
Azenta
-- 2.222 -- 2.16x
BNGO
Bionano Genomics
21.3% -0.388 150.7% 0.82x
BRKR
Bruker
53.77% 0.828 33.24% 0.66x
HBIO
Harvard Bioscience
70.79% 2.159 143.69% 0.34x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BIO
Bio-Rad Laboratories
$306M $23.7M -25.43% -29.59% 16.3% $95.5M
AKYA
Akoya Biosciences
$9.9M -$13.3M -52.81% -338.02% -78.8% -$7.4M
AZTA
Azenta
$65.9M -$12.6M -3.48% -3.48% -8.77% $7M
BNGO
Bionano Genomics
$2.9M -$8.5M -112.51% -141.6% -46.62% -$2.8M
BRKR
Bruker
$391.2M $65.7M 2.11% 4.53% 4.77% $39M
HBIO
Harvard Bioscience
$12.2M -$1.5M -62.88% -103.83% -229.6% $2.3M

Bio-Rad Laboratories vs. Competitors

  • Which has Higher Returns BIO or AKYA?

    Akoya Biosciences has a net margin of 10.93% compared to Bio-Rad Laboratories's net margin of -94.07%. Bio-Rad Laboratories's return on equity of -29.59% beat Akoya Biosciences's return on equity of -338.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIO
    Bio-Rad Laboratories
    52.27% $2.29 $7.9B
    AKYA
    Akoya Biosciences
    59.33% -$0.32 $70.6M
  • What do Analysts Say About BIO or AKYA?

    Bio-Rad Laboratories has a consensus price target of $318.67, signalling upside risk potential of 39.07%. On the other hand Akoya Biosciences has an analysts' consensus of $1.88 which suggests that it could grow by 54.3%. Given that Akoya Biosciences has higher upside potential than Bio-Rad Laboratories, analysts believe Akoya Biosciences is more attractive than Bio-Rad Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIO
    Bio-Rad Laboratories
    2 2 0
    AKYA
    Akoya Biosciences
    0 7 0
  • Is BIO or AKYA More Risky?

    Bio-Rad Laboratories has a beta of 0.999, which suggesting that the stock is 0.087999999999999% less volatile than S&P 500. In comparison Akoya Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BIO or AKYA?

    Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akoya Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Akoya Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIO or AKYA?

    Bio-Rad Laboratories quarterly revenues are $585.4M, which are larger than Akoya Biosciences quarterly revenues of $16.6M. Bio-Rad Laboratories's net income of $64M is higher than Akoya Biosciences's net income of -$15.7M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Akoya Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.53x versus 0.76x for Akoya Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIO
    Bio-Rad Laboratories
    2.53x -- $585.4M $64M
    AKYA
    Akoya Biosciences
    0.76x -- $16.6M -$15.7M
  • Which has Higher Returns BIO or AZTA?

    Azenta has a net margin of 10.93% compared to Bio-Rad Laboratories's net margin of -28.21%. Bio-Rad Laboratories's return on equity of -29.59% beat Azenta's return on equity of -3.48%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIO
    Bio-Rad Laboratories
    52.27% $2.29 $7.9B
    AZTA
    Azenta
    45.94% -$0.88 $1.7B
  • What do Analysts Say About BIO or AZTA?

    Bio-Rad Laboratories has a consensus price target of $318.67, signalling upside risk potential of 39.07%. On the other hand Azenta has an analysts' consensus of $41.60 which suggests that it could grow by 53.51%. Given that Azenta has higher upside potential than Bio-Rad Laboratories, analysts believe Azenta is more attractive than Bio-Rad Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIO
    Bio-Rad Laboratories
    2 2 0
    AZTA
    Azenta
    1 5 0
  • Is BIO or AZTA More Risky?

    Bio-Rad Laboratories has a beta of 0.999, which suggesting that the stock is 0.087999999999999% less volatile than S&P 500. In comparison Azenta has a beta of 1.638, suggesting its more volatile than the S&P 500 by 63.767%.

  • Which is a Better Dividend Stock BIO or AZTA?

    Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIO or AZTA?

    Bio-Rad Laboratories quarterly revenues are $585.4M, which are larger than Azenta quarterly revenues of $143.4M. Bio-Rad Laboratories's net income of $64M is higher than Azenta's net income of -$40.5M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.53x versus 2.06x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIO
    Bio-Rad Laboratories
    2.53x -- $585.4M $64M
    AZTA
    Azenta
    2.06x -- $143.4M -$40.5M
  • Which has Higher Returns BIO or BNGO?

    Bionano Genomics has a net margin of 10.93% compared to Bio-Rad Laboratories's net margin of -48.04%. Bio-Rad Laboratories's return on equity of -29.59% beat Bionano Genomics's return on equity of -141.6%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIO
    Bio-Rad Laboratories
    52.27% $2.29 $7.9B
    BNGO
    Bionano Genomics
    45.5% -$1.15 $61.2M
  • What do Analysts Say About BIO or BNGO?

    Bio-Rad Laboratories has a consensus price target of $318.67, signalling upside risk potential of 39.07%. On the other hand Bionano Genomics has an analysts' consensus of $7.33 which suggests that it could grow by 98.2%. Given that Bionano Genomics has higher upside potential than Bio-Rad Laboratories, analysts believe Bionano Genomics is more attractive than Bio-Rad Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIO
    Bio-Rad Laboratories
    2 2 0
    BNGO
    Bionano Genomics
    0 2 0
  • Is BIO or BNGO More Risky?

    Bio-Rad Laboratories has a beta of 0.999, which suggesting that the stock is 0.087999999999999% less volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.367, suggesting its more volatile than the S&P 500 by 136.713%.

  • Which is a Better Dividend Stock BIO or BNGO?

    Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIO or BNGO?

    Bio-Rad Laboratories quarterly revenues are $585.4M, which are larger than Bionano Genomics quarterly revenues of $6.5M. Bio-Rad Laboratories's net income of $64M is higher than Bionano Genomics's net income of -$3.1M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.53x versus 0.16x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIO
    Bio-Rad Laboratories
    2.53x -- $585.4M $64M
    BNGO
    Bionano Genomics
    0.16x -- $6.5M -$3.1M
  • Which has Higher Returns BIO or BRKR?

    Bruker has a net margin of 10.93% compared to Bio-Rad Laboratories's net margin of 2.17%. Bio-Rad Laboratories's return on equity of -29.59% beat Bruker's return on equity of 4.53%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIO
    Bio-Rad Laboratories
    52.27% $2.29 $7.9B
    BRKR
    Bruker
    48.82% $0.11 $4B
  • What do Analysts Say About BIO or BRKR?

    Bio-Rad Laboratories has a consensus price target of $318.67, signalling upside risk potential of 39.07%. On the other hand Bruker has an analysts' consensus of $55.13 which suggests that it could grow by 49.12%. Given that Bruker has higher upside potential than Bio-Rad Laboratories, analysts believe Bruker is more attractive than Bio-Rad Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIO
    Bio-Rad Laboratories
    2 2 0
    BRKR
    Bruker
    5 8 0
  • Is BIO or BRKR More Risky?

    Bio-Rad Laboratories has a beta of 0.999, which suggesting that the stock is 0.087999999999999% less volatile than S&P 500. In comparison Bruker has a beta of 1.228, suggesting its more volatile than the S&P 500 by 22.782%.

  • Which is a Better Dividend Stock BIO or BRKR?

    Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.54% to investors and pays a quarterly dividend of $0.05 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BIO or BRKR?

    Bio-Rad Laboratories quarterly revenues are $585.4M, which are smaller than Bruker quarterly revenues of $801.4M. Bio-Rad Laboratories's net income of $64M is higher than Bruker's net income of $17.4M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Bruker's PE ratio is 71.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.53x versus 1.62x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIO
    Bio-Rad Laboratories
    2.53x -- $585.4M $64M
    BRKR
    Bruker
    1.62x 71.10x $801.4M $17.4M
  • Which has Higher Returns BIO or HBIO?

    Harvard Bioscience has a net margin of 10.93% compared to Bio-Rad Laboratories's net margin of -231.19%. Bio-Rad Laboratories's return on equity of -29.59% beat Harvard Bioscience's return on equity of -103.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIO
    Bio-Rad Laboratories
    52.27% $2.29 $7.9B
    HBIO
    Harvard Bioscience
    55.96% -$1.14 $50.8M
  • What do Analysts Say About BIO or HBIO?

    Bio-Rad Laboratories has a consensus price target of $318.67, signalling upside risk potential of 39.07%. On the other hand Harvard Bioscience has an analysts' consensus of $3.00 which suggests that it could grow by 955.22%. Given that Harvard Bioscience has higher upside potential than Bio-Rad Laboratories, analysts believe Harvard Bioscience is more attractive than Bio-Rad Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIO
    Bio-Rad Laboratories
    2 2 0
    HBIO
    Harvard Bioscience
    1 1 0
  • Is BIO or HBIO More Risky?

    Bio-Rad Laboratories has a beta of 0.999, which suggesting that the stock is 0.087999999999999% less volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.441, suggesting its more volatile than the S&P 500 by 44.128%.

  • Which is a Better Dividend Stock BIO or HBIO?

    Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIO or HBIO?

    Bio-Rad Laboratories quarterly revenues are $585.4M, which are larger than Harvard Bioscience quarterly revenues of $21.8M. Bio-Rad Laboratories's net income of $64M is higher than Harvard Bioscience's net income of -$50.3M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.53x versus 0.14x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIO
    Bio-Rad Laboratories
    2.53x -- $585.4M $64M
    HBIO
    Harvard Bioscience
    0.14x -- $21.8M -$50.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth
Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth

Microsoft (NASDAQ:MSFT) has been among the top growth stocks of…

Is Tesla Stock Overvalued or a Buy for the Next Decade?
Is Tesla Stock Overvalued or a Buy for the Next Decade?

Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…

Is Apple Stock Undervalued or Overvalued?
Is Apple Stock Undervalued or Overvalued?

For many years, Apple (NASDAQ:AAPL) was just about the perfect…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
80
SBET alert for May 29

SharpLink Gaming [SBET] is up 70.34% over the past day.

Buy
100
BOX alert for May 29

Box [BOX] is down 0.84% over the past day.

Sell
22
OKTA alert for May 29

Okta [OKTA] is up 1.58% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock